ICD code C34.90 – Unspecified lung or bronchus cancer

Key takeaways

C34.90 is for a confirmed primary lung cancer when no report in the record names the site or the side.

Read the imaging, pathology and operative notes first, because a named lobe or side moves the claim to a more specific C34 code.

A lung metastasis from another primary never takes C34.90. Code it to C78.00, C78.01 or C78.02 instead.

C34 carries use-additional-code notes for tobacco, so add F17.-, Z87.891, Z72.0 or the exposure code the chart documents.

Pabau sends US claims electronically through Claim.MD and tracks prior authorization codes on each patient’s case.

ICD-10 code C34.90: Unspecified lung cancer, and when it’s allowed

ICD-10 code C34.90 is the billable code for a confirmed primary lung or bronchus cancer when no report names the site or the side. Its descriptor in CMS’s FY2027 ICD-10-CM files reads “Malignant neoplasm of unspecified part of unspecified bronchus or lung.” The tabular list also indexes “Lung cancer NOS” to it.

The C34 category carries use-additional-code notes for tobacco, and they apply to C34.90. When the chart documents tobacco use, dependence, history or exposure, add the matching code. The options are F17.-, Z72.0, Z87.891, Z77.22, Z57.31 or P96.81.

The CDC/NCHS ICD-10-CM web tool shows the same notes. Chapter 2 of the ICD-10-CM Official Guidelines accepts unspecified codes when the record supports no greater detail. Coders are still expected to query the physician before settling for one.

Where C34.90 sits in the C34 lung cancer family

The C34 category splits primary lung cancer by site and side. C34.90 is the fallback for a record that names neither.

C34.91 and C34.92 name the side but not the site, while C34.90 names neither. So when the physician writes “right lung cancer” without a lobe, C34.91 is the better code. The middle lobe is the one site with a single code, C34.2, because only the right lung has one.

What C34.90 covers, and what it never covers

C34.90 takes any histologic type of primary bronchus or lung cancer when the record names no site or side. That puts both main lung cancer types under it.

Included diagnoses

• Lung cancer NOS, the inclusion term the tabular list places under C34.90.
• Non-small cell lung cancer, including adenocarcinoma, squamous cell and large cell carcinoma, when no report names the site or side.
• Small cell lung cancer when no report names the site or side.

Excluded diagnoses (do not use C34.90)

• Mesothelioma: Coded to C45.-, per the Excludes1 note at the C30-C39 block.
• Kaposi sarcoma of the lung: Coded to C46.5-, per the Excludes1 note at C34.
• Malignant carcinoid tumor of the bronchus and lung: Coded to C7A.090, per the Excludes1 note at C34.
• Secondary malignant neoplasm of the lung: A metastasis from another primary goes to C78.00, C78.01 or C78.02.
• Carcinoma in situ of bronchus and lung: Coded to D02.20, D02.21 or D02.22.
• Main bronchus cancer: Coded to C34.00, C34.01 or C34.02, even when the side is unknown.

ICD-10-CM claims carry no separate histology code. The pathology report records whether it’s adenocarcinoma, squamous cell or small cell, but C34.90 covers all of them.

Pick the most specific C34 code the chart supports

C34.90 fits only when the record supports no site or side. It’s never a shortcut for a chart nobody read in full. Work through the questions below in order, and stop at the first one the documentation answers.

Common chart scenarios

Payers notice when an unspecified code sits beside imaging that names a side. A C34.90 claim filed while the CT report shows a right upper lobe mass is a documentation mismatch. It can draw a records request or a denial.

Primary or metastatic? The C78.0- trap behind C34.90

The distinction with the biggest consequences in lung cancer coding is primary versus secondary. C34.90 means the cancer started in the bronchus or lung. C78.0- means it spread to the lung from somewhere else.

Sequencing follows where the treatment is aimed. Under the Chapter 2 guidelines, treatment aimed only at a lung metastasis puts C78.0- first, even while the primary is still present. An encounter solely for chemotherapy leads with Z51.11 instead, then the cancer codes. C34.90 doesn’t belong on either claim when the lung lesion is secondary.

Codes that usually ride along with C34.90

ICD-10-CM doesn’t build stage into C34.90. Spread and risk factors go on the claim as additional codes, while the TNM stage stays in the clinical record.

For a current cigarette smoker without complications, F17.210 is the usual tobacco code. AJCC TNM staging supports medical necessity and treatment authorization. It never adds a digit to C34.90 or replaces it.

What the chart needs before you submit C34.90

Three documentation elements are required before C34.90 goes on a claim, and a fourth is best practice.

• Confirmed malignancy: The physician documents a confirmed diagnosis, not “suspected”, “possible” or “rule out”. Outpatient coders don’t code uncertain diagnoses as confirmed. Inpatient coders may code an uncertain diagnosis documented at discharge as if it were established.
• Primary site: The record shows the lung or bronchus is where the cancer started, not where it spread. Pathology that establishes origin is the strongest evidence.
• Site and side status: A report that names the site or side moves the claim to a more specific code. Otherwise, the record shows they can’t be determined. A note such as “bilateral pulmonary involvement, primary side undetermined” supports C34.90.
• Histologic type (best practice): No histology code goes on the claim, but keep the pathology report in the chart for audits. Recording the histology in the problem list helps the next coder too.

A pre-submission review is what turns this documentation into a clean claim. It catches a missing side or an unconfirmed diagnosis before the payer does.

How a C34.90 claim moves from chart to payment

Most lung cancer claims follow the same four steps. Each one has its own failure point.

1. Chart review. Read the physician note with the CT, PET, pathology and operative reports. Confirm primary versus metastatic, and look for any named site or side.
2. Coding. Assign the most specific C34 code the chart supports. Add metastasis and tobacco codes, and sequence by where the treatment is aimed.
3. Authorization check. Match each CPT code to the payer’s prior authorization list. Record the auth number before the service, not after.
4. Submission and remittance. Send the claim, then read the remittance. Trace any denial code back to the step where it started.

Before you submit: A C34.90 checklist

• Malignancy is confirmed in writing, not “suspected” or “rule out”, on outpatient claims.
• The lung is confirmed as the primary site, and any other primary carries its own code.
• Imaging, pathology and operative reports have been checked for a site or side.
• A physician query went out, and was answered, where reports conflict or stay silent.
• A tobacco code is on the claim when use, dependence, history or exposure is documented.
• The prior authorization number is on the claim for PET, immunotherapy or SBRT where the payer requires one.
• The payer’s own rules are checked, including any records it asks for with unspecified codes.

CPT codes that usually travel with C34.90

C34.90 tends to pair with the same procedure codes from diagnosis through treatment. Chemotherapy infusion starts with 96413 for the first hour. Staging PET/CT from skull base to mid-thigh bills as 78815.

A peripheral lesion often needs radial endobronchial ultrasound to reach. That adds 31654 to the base bronchoscopy code, and the biopsy result decides between C34 and C78.0-.

Prior authorization rules by payer for C34.90 claims

Authorization rules for C34.90 claims depend on the payer and the service. Medicare, Medicare Advantage, Medicaid and commercial plans each set their own policies for lung cancer care.

Medicare fee-for-service

Medicare covers most lung cancer diagnostics and treatment under its NCDs and LCDs. NCD 220.6.17 covers FDG PET for initial treatment strategy in solid tumors when its conditions are met. Traditional Medicare doesn’t require prior authorization for chemotherapy, but Part B drug policies govern J-code coverage.

Medicare Advantage and commercial payers

Medicare Advantage plans may require prior authorization that traditional Medicare doesn’t. Many require it for PET scans, immunotherapy infusions and stereotactic body radiotherapy (SBRT). A claim for an auth-required service without the authorization number will deny, whatever the diagnosis.

Commercial payer policies vary widely. Some request records when C34.90 arrives with imaging that names a side, so code to the side whenever the chart supports it.

Medicaid

Each state Medicaid agency or managed-care plan sets its own policies for unspecified diagnosis codes. Some accept C34.90 without extra review, and others want supporting documentation for high-cost oncology claims. Check the state agency or plan’s rules each year, because they can change with the October code update.

Common C34.90 mistakes that get claims denied

C34.90 denials trace back to a handful of root causes, and each one can be caught before submission. A wider denial management process then handles the appeals and tracking. The table covers the patterns specific to C34.90.

Our guide to denial codes explains each adjustment code and its appeal path. CO-4 relates to a missing or inconsistent modifier, so it rarely points at a diagnosis problem. Laterality appeals land best with a physician attestation explaining why the side couldn’t be documented.

Is C34.90 still valid in FY2026 and FY2027?

Yes. C34.90 is valid in FY2026, which took effect on October 1, 2025, and in FY2027, which took effect on October 1, 2026. The FY2027 code files keep the descriptor “Malignant neoplasm of unspecified part of unspecified bronchus or lung” unchanged.

The C34 use-additional-code notes for tobacco and the Excludes1 notes for Kaposi sarcoma and malignant carcinoid carry into FY2027 too. Check them each October, when the new edition takes effect.

The CMS ICD-10 codes page publishes the annual code files, addenda and official guidelines. It’s the most reliable place to confirm a C34 revision. The AAPC Codify ICD-10-CM lookup and ICD List mirror the official data for quick checks.

How Pabau keeps C34.90 claims moving to payment

Lung cancer claims tend to stall at the same points. An authorization number is missing, eligibility wasn’t checked, or a remittance sits unread while the denial window runs.

Pabau, the practice management platform we build, sends US claims through Claim.MD in the CMS-1500/837P format. Its claims management software runs eligibility checks before the visit and brings in ERA remittances when payers respond. Your team files secondary claims from the same patient record.

Prior authorization sits on the patient’s case in Pabau. The auth code, dates and sessions are tracked there, and you get a warning when one is missing. That matters for PET scans and immunotherapy, where a missing auth number denies the claim regardless of the code.

Keep lung cancer claims moving

Pabau sends US claims through Claim.MD, runs eligibility checks and brings in ERA remittances. It tracks each prior authorization on the patient’s case and warns you when one is missing.

Book a demo

Conclusion

Treat C34.90 as the code you land on after reading the chart, not the one you start from. Read the CT, PET and pathology reports before you code. Query the physician when the reports disagree or leave the site out.

Two habits carry most of the weight. Confirm the lung is the primary before any C34 code goes on the claim, and add the tobacco code whenever the chart documents it. The cost is a few minutes of chart review per encounter, against a records request or a recoupment later.

Book a demo to see how Pabau handles Claim.MD submission, eligibility checks and prior authorization tracking for your oncology claims.

Continue your research

Need a framework for working denials? Denial management in healthcare covers root-cause analysis, appeal strategies and tracking for busy practices.

Looking for clearinghouse guidance? Our Claim.MD clearinghouse guide explains how electronic claim validation works and what payer edits to expect.

Coding tobacco use alongside lung cancer? ICD-10 code Z72.0 covers tobacco use without dependence and when to report it.

Keeping oncology billing audit-ready? Medical billing compliance sets out the rules and controls that keep claims defensible.

Want to understand the full revenue cycle? What is revenue cycle management walks through how claims move from encounter to payment.

Frequently asked questions